Skip to main content
. 2018 Feb 15;16:6. doi: 10.1186/s12962-018-0088-9

Table 2.

Transition probabilities for each cycle of the markov model (Unit: %)

Base-case value Range PSA distribution PSA parameters Source
Perinatal infection to
 Immune tolerance/inactive state 89 80–90 Beta α = 172.55; β = 30.45 [20, 35]
Immune tolerance/Inactive state to
 Chronic hepatitis (years)
  < 25  0.43 0.3–0.65 Beta α = 29.32; β = 6144.29 [19]
  ≥ 25 3 2.9–7.3 Beta α = 20.35; β = 378.64 [19]
 Chronic hepatitis to
 Immune tolerance/inactive state (years)
  < 25 9 0–16.3 Beta α = 3.59; β = 40.49 [19]
  ≥ 25 10 8.3–16.3 Beta α = 33.05; β = 235.63 [19]
 Compensated cirrhosis (years)
  < 25 0.065 0.01–0.12 Beta α = 5.58; β = 8582.87 [19]
  ≥ 25 1.5 1–5.7 Beta α = 7.82; β = 225.69 [19]
  HCC 0.5 0.2–1 Beta α = 8.94; β = 1481.06 [20, 36]
  Disease-related death 0.9 0.3–3.6 Beta α = 5.46; β = 274.46 [20, 36]
 Compensated cirrhosis to
  Decompensated cirrhosis 5.4 2.8–15 Beta α = 7.67; β = 78.49 [20, 36]
  HCC 3.3 0.5–6.6 Beta α = 5.19; β = 141.04 [20, 36]
  Disease-related death 3.5 0–8 Beta α = 3.8; β = 91.2 [17, 20]
 Decompensated cirrhosis to
  HCC 7.1 0.15–10 Beta α = 3.98; β = 74.46 [17, 20, 36]
  Disease-related death 15 9.9–50 Dirichlet List (20;75;5) [20, 36]
 HCC to
  Disease-related death 54 8.1–70 Dirichlet List (20;75;5) [20, 36]

HCC hepatocellular carcinoma, PSA probabilistic sensitivity analysis